-
1
-
-
84978359538
-
-
7 ed. Brussels, Belgium: International Diabetes Federation
-
International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation 2015.
-
(2015)
IDF Diabetes Atlas
-
-
-
2
-
-
80051986265
-
Globalization of Diabetes: The role of diet, lifestyle, and genes
-
Frank BH. Globalization of Diabetes: the role of diet, lifestyle, and genes. Diab Care 2011; 34: 1249-57.
-
(2011)
Diab Care
, vol.34
, pp. 1249-1257
-
-
Frank, B.H.1
-
3
-
-
84912098926
-
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
-
Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?. World J Diabetes 2014; 5: 444-70.
-
(2014)
World J Diabetes
, vol.5
, pp. 444-470
-
-
Martín-Timón, I.1
Sevillano-Collantes, C.2
Segura-Galindo, A.3
-
4
-
-
0027370108
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
-
The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1995; 329: 977-986.
-
(1995)
N Engl J Med
, vol.329
, pp. 977-986
-
-
-
5
-
-
84960878943
-
Standards of Medical Care in Diabetes-2016: Summary of Revisions
-
American Diabetes Association. Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diab Care 2016; 39: Suppl 1: S4-5.
-
(2016)
Diab Care
, vol.39
, pp. S4-S5
-
-
-
6
-
-
84866268783
-
Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care 2012; 35: 1364-79.
-
(2012)
Diab Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
7
-
-
84885997413
-
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
-
Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-87.
-
(2013)
Eur Heart J
, vol.34
, pp. 3035-3087
-
-
Ryden, L.1
Grant, P.J.2
Anker, S.D.3
-
8
-
-
84969296935
-
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
-
Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015; 6: 1246-58.
-
(2015)
World J Diabetes
, vol.6
, pp. 1246-1258
-
-
Leon, B.M.1
Maddox, T.M.2
-
9
-
-
84875462788
-
Impact of diabetes on cardiovascular disease: An update
-
Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens 2013; 2013: 653789.
-
(2013)
Int J Hypertens
, pp. 2013
-
-
Matheus, A.S.1
Tannus, L.R.2
Cobas, R.A.3
-
10
-
-
36349001748
-
Cardiovascular disease and type 2 diabetes mellitus: A multifaceted symbiosis
-
Johansen OE. Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis. Scand J Clin Lab Invest 2007; 67: 786-800.
-
(2007)
Scand J Clin Lab Invest
, vol.67
, pp. 786-800
-
-
Johansen, O.E.1
-
11
-
-
80054095684
-
Diabetes mellitus and cardiovascular disease
-
Li YW, Aronow WS. Diabetes mellitus and cardiovascular disease. J Clinic Exp Cardiol 2011; 2: 2.
-
(2011)
J Clinic Exp Cardiol
, vol.2
, pp. 2
-
-
Li, Y.W.1
Aronow, W.S.2
-
12
-
-
38149062075
-
Is glycemic control improving in U.S. adults?
-
Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults?. Diab Care 2008; 31: 81-6.
-
(2008)
Diab Care
, vol.31
, pp. 81-86
-
-
Hoerger, T.J.1
Segel, J.E.2
Gregg, E.W.3
-
13
-
-
79955752170
-
Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations
-
Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-13.
-
(2011)
Ann Intern Med
, vol.154
, pp. 602-613
-
-
Bennett, W.L.1
Maruthur, N.M.2
Singh, S.3
-
14
-
-
84901768284
-
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
-
Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008-17.
-
(2014)
Lancet
, vol.383
, pp. 2008-2017
-
-
Holman, R.R.1
Sourij, H.2
Califf, R.M.3
-
15
-
-
84861098920
-
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
-
Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Curr Diab Rep 2012; 12: 230-38.
-
(2012)
Curr Diab Rep
, vol.12
, pp. 230-238
-
-
Abdul-Ghani, M.A.1
Norton, L.2
Defronzo, R.A.3
-
16
-
-
84928911112
-
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: A growing class of antidiabetic agents
-
Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context 2014; 3: 212-64
-
(2014)
Drugs Context
, vol.3
, pp. 212-264
-
-
Vivian, E.M.1
-
17
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
18
-
-
84855525536
-
Cardiovascular risk of oral antidiabetic drugs: Current evidence and regulatory requirements for new drugs
-
Panicker GK, Karnad DR, Salvi V, et al. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. J Assoc Physicians India 2012; 60: 56-61.
-
(2012)
J Assoc Physicians India
, vol.60
, pp. 56-61
-
-
Panicker, G.K.1
Karnad, D.R.2
Salvi, V.3
-
19
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
-
20
-
-
77954988618
-
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
-
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-8.
-
(2010)
JAMA
, vol.304
, pp. 411-418
-
-
Graham, D.J.1
Ouellet-Hellstrom, R.2
Macurdy, T.E.3
-
21
-
-
84880919064
-
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
-
Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013; 166: 240-9.
-
(2013)
Am Heart J
, vol.166
, pp. 240-249
-
-
Mahaffey, K.W.1
Hafley, G.2
Dickerson, S.3
-
22
-
-
84937053742
-
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
-
Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-42.
-
(2015)
N Engl J Med
, vol.373
, pp. 232-242
-
-
Green, J.B.1
Bethel, M.A.2
Armstrong, P.W.3
-
23
-
-
84930085787
-
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, doubleblind trial
-
Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, doubleblind trial. Lancet 2015; 385: 2067-76.
-
(2015)
Lancet
, vol.385
, pp. 2067-2076
-
-
Zannad, F.1
Cannon, C.P.2
Cushman, W.C.3
-
24
-
-
84880688845
-
GLP-1 receptor agonists: Effects on cardiovascular risk reduction
-
Lorber, D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Therap 2013; 31: 238-49.
-
(2013)
Cardiovasc Therap
, vol.31
, pp. 238-249
-
-
Lorber, D.1
-
25
-
-
85014593796
-
Potential cardiovascular effects of the glucagonlike peptide-1 receptor agonists
-
Chilton RJ. Potential cardiovascular effects of the glucagonlike peptide-1 receptor agonists. J Diabetes Metab 2015; 6: 483.
-
(2015)
J Diabetes Metab
, vol.6
, pp. 483
-
-
Chilton, R.J.1
-
26
-
-
83655193529
-
The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia
-
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diab Obes and Metab 2011; 14: 5-14.
-
(2011)
Diab Obes and Metab
, vol.14
, pp. 5-14
-
-
Defronzo, R.A.1
Davidson, J.A.2
Del Prato, S.3
-
27
-
-
78651406659
-
SGLT2 mediates glucose reabsorption in the early proximal tubule
-
Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 201; 22: 104-12.
-
J am Soc Nephrol 201
, vol.22
, pp. 104-112
-
-
Vallon, V.1
Platt, K.A.2
Cunard, R.3
-
28
-
-
0028044629
-
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose
-
Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397-404.
-
(1994)
J Clin Invest
, vol.93
, pp. 397-404
-
-
Kanai, Y.1
Lee, W.S.2
You, G.3
-
29
-
-
33846023326
-
Active sugar transport in health and disease
-
Wright E, Hirayama B, Loo D. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
-
(2007)
J Intern Med
, vol.261
, pp. 32-43
-
-
Wright, E.1
Hirayama, B.2
Loo, D.3
-
30
-
-
0032146567
-
Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus
-
Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998; 102: 619-24.
-
(1998)
J Clin Invest
, vol.102
, pp. 619-624
-
-
Meyer, C.1
Stumvoll, M.2
Nadkarni, V.3
-
31
-
-
8544226262
-
Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes
-
Meyer C, Woerle HJ, Dostou JM, et al. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 287: E1049-56.
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
, pp. E1049-E1056
-
-
Meyer, C.1
Woerle, H.J.2
Dostou, J.M.3
-
32
-
-
0015122757
-
Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects
-
Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-9.
-
(1971)
Scand J Clin Lab Invest
, vol.28
, pp. 101-109
-
-
Mogensen, C.E.1
-
33
-
-
84929354073
-
Sodium-glucose cotransport inhibitors: Mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease
-
Vlotides G, Mertens PR. Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. Nephrol Dial Transplant 2014; pii: gfu299.
-
(2014)
Nephrol Dial Transplant
-
-
Vlotides, G.1
Mertens, P.R.2
-
34
-
-
33644688031
-
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
-
Rahmoune H, Thompson P, Ward J, Smith C, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-34.
-
(2005)
Diabetes
, vol.54
, pp. 3427-3434
-
-
Rahmoune, H.1
Thompson, P.2
Ward, J.3
Smith, C.4
Hong, G.5
Brown, J.6
-
35
-
-
1242272759
-
The sodium/glucose contrasport family SLC5
-
Wright EM; Turk E. The sodium/glucose contrasport family SLC5. Pflugers Arch 2004; 447: 510-8.
-
(2004)
Pflugers Arch
, vol.447
, pp. 510-518
-
-
Wright, E.M.1
Turk, E.2
-
37
-
-
0000298609
-
Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro
-
Alvarado F, Crane RK. Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro. Biochim Biophys Acta 1962; 56: 170-2.
-
(1962)
Biochim Biophys Acta
, vol.56
, pp. 170-172
-
-
Alvarado, F.1
Crane, R.K.2
-
38
-
-
0023275573
-
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
-
Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-5.
-
(1987)
J Clin Invest
, vol.79
, pp. 1510-1515
-
-
Rossetti, L.1
Smith, D.2
Shulman, G.I.3
-
39
-
-
0023571397
-
Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats
-
Rossetti L, Shulman GI, Zawalich W, et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987; 80: 1037-44.
-
(1987)
J Clin Invest
, vol.80
, pp. 1037-1044
-
-
Rossetti, L.1
Shulman, G.I.2
Zawalich, W.3
-
41
-
-
84888346204
-
SGLT-2 inhibitors and their potential in the treatment of diabetes
-
Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013; 6: 453-67.
-
(2013)
Diabetes Metab Syndr Obes
, vol.6
, pp. 453-467
-
-
Rosenwasser, R.F.1
Sultan, S.2
Sutton, D.3
-
42
-
-
84923448295
-
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
-
Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015; 12: 90-100.
-
(2015)
Diab Vasc Dis Res
, vol.12
, pp. 90-100
-
-
Inzucchi, S.E.1
Zinman, B.2
Wanner, C.3
-
43
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
-
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
-
(2000)
BMJ
, vol.321
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
44
-
-
84948716657
-
Efficacy and safety of sodiumglucose cotransporter 2 inhibitors in type 2 diabetes: A metaanalysis of randomized controlled trials for 1 to 2 years
-
Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodiumglucose cotransporter 2 inhibitors in type 2 diabetes: a metaanalysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications. 2015; 29: 1295-303.
-
(2015)
J Diabetes Complications
, vol.29
, pp. 1295-1303
-
-
Liu, X.Y.1
Zhang, N.2
Chen, R.3
-
45
-
-
84895484977
-
Dapagliflozin treatment for type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
-
Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2014; 30: 204-21.
-
(2014)
Diabetes Metab Res Rev
, vol.30
, pp. 204-221
-
-
Zhang, M.1
Zhang, L.2
Wu, B.3
-
46
-
-
84898789114
-
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-analysis
-
Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 2014; 16: n433-42.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. n433-n442
-
-
Goring, S.1
Hawkins, N.2
Wygant, G.3
-
47
-
-
80155124676
-
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
-
Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-22.
-
(2011)
Diabetes Care
, vol.34
, pp. 2015-2022
-
-
Nauck, M.A.1
Del Prato, S.2
Meier, J.J.3
-
48
-
-
77953857048
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebocontrolled trial
-
Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebocontrolled trial. Lancet 2010; 375: 2223-33.
-
(2010)
Lancet
, vol.375
, pp. 2223-2233
-
-
Bailey, C.J.1
Gross, J.L.2
Pieters, A.3
-
49
-
-
77956921439
-
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
-
Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-24.
-
(2010)
Diabetes Care
, vol.33
, pp. 2217-2224
-
-
Ferrannini, E.1
Ramos, S.J.2
Salsali, A.3
-
50
-
-
80052524011
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial
-
Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-38.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 928-938
-
-
Strojek, K.1
Yoon, K.H.2
Hruba, V.3
-
51
-
-
84912533839
-
Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and metaanalysis
-
Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and metaanalysis. Diabetes Obes Metab 2014; 16: 984-93.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 984-993
-
-
Liakos, A.1
Karagiannis, T.2
Athanasiadou, E.3
-
52
-
-
84885954870
-
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial
-
Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-19.
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, pp. 208-219
-
-
Roden, M.1
Weng, J.2
Eilbracht, J.3
-
53
-
-
84901455931
-
Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
-
Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-9.
-
(2014)
Diabetes Care
, vol.37
, pp. 1650-1659
-
-
Häring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
-
54
-
-
84885952950
-
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
-
Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-404.
-
(2013)
Diabetes Care
, vol.36
, pp. 3396-3404
-
-
Häring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
-
55
-
-
84892477577
-
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial
-
Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147-58.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 147-158
-
-
Kovacs, C.S.1
Seshiah, V.2
Swallow, R.3
-
56
-
-
84903511385
-
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
-
Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37: 1815-23.
-
(2014)
Diabetes Care
, vol.37
, pp. 1815-1823
-
-
Rosenstock, J.1
Jelaska, A.2
Frappin, G.3
-
57
-
-
84929676338
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: Systematic review and metaanalysis
-
Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and metaanalysis. Eur J Clin Pharmacol 2014; 70: 1149-58.
-
(2014)
Eur J Clin Pharmacol
, vol.70
, pp. 1149-1158
-
-
Yang, X.P.1
Lai, D.2
Zhong, X.Y.3
-
58
-
-
84887997289
-
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial
-
Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-92.
-
(2013)
Diabetologia
, vol.56
, pp. 2582-2592
-
-
Lavalle-Gonzalez, F.J.1
Januszewicz, A.2
Davidson, J.3
-
59
-
-
84891784200
-
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial
-
Schernthaner G, Gross JL, A Rosenstock, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-15.
-
(2013)
Diabetes Care
, vol.36
, pp. 2508-2515
-
-
Schernthaner, G.1
Gross, J.L.2
Rosenstock, A.3
-
60
-
-
84880543926
-
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial
-
Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013; 41: 72-84.
-
(2013)
Hosp Pract (1995)
, vol.41
, pp. 72-84
-
-
Bode, B.1
Stenlof, K.2
Sullivan, D.3
-
61
-
-
84874291673
-
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
-
Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: b372-82.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. b372-b382
-
-
Stenlof, K.1
Cefalu, W.T.2
Kim, K.A.3
-
62
-
-
84922108911
-
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2diabetes: ILLUMINATE, a randomized, double-blind, placebocontrolled study
-
Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2diabetes: ILLUMINATE, a randomized, double-blind, placebocontrolled study. Diabetes Obes Metab 2015; 17: 304-8.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 304-308
-
-
Kashiwagi, A.1
Kazuta, K.2
Goto, K.3
-
63
-
-
84921328874
-
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: Results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study
-
Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab 2015; 17: 152-60.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 152-160
-
-
Kashiwagi, A.1
Takahashi, H.2
Ishikawa, H.3
-
64
-
-
84876344111
-
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled onmetformin: A dose-finding study
-
Wilding JP, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled onmetformin: a dose-finding study. Diabetes Obes Metab 2013; 15: 403-9.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 403-409
-
-
Wilding, J.P.1
Ferrannini, E.2
Fonseca, V.A.3
-
65
-
-
84902245089
-
Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A 12-week, randomized, placebo-controlled, phase II study
-
Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin 2014; 30: 1219-30.
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 1219-1230
-
-
Seino, Y.1
Sasaki, T.2
Fukatsu, A.3
-
66
-
-
84903557735
-
Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetesmellitus: A randomized, double-blind, placebo-controlled, phase 3 study
-
Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetesmellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30: 1245-55.
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 1245-1255
-
-
Seino, Y.1
Sasaki, T.2
Fukatsu, A.3
-
67
-
-
84899558137
-
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined Phase 2 and 3 randomized, placebo-controlled, doubleblind, parallel-group comparative study
-
Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, doubleblind, parallel-group comparative study. Cardiovasc Diabetol 2014; 13: 65.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 65
-
-
Kaku, K.1
Watada, H.2
Iwamoto, Y.3
-
68
-
-
84902294790
-
A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus
-
Ikeda S, Takano Y, Cynshi O, et al. A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetologia 2012; 55 (suppl 1): S1-S538.
-
(2012)
Diabetologia
, vol.55
, pp. SS1-S538
-
-
Ikeda, S.1
Takano, Y.2
Cynshi, O.3
-
69
-
-
0034641550
-
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
-
Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9.
-
(2000)
BMJ
, vol.321
, pp. 412-419
-
-
Adler, A.I.1
Stratton, I.M.2
Neil, H.A.3
-
70
-
-
84943187885
-
Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: A valuable effect of a novel antidiabetic class?
-
Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens 2015; 33: 2185-97.
-
(2015)
J Hypertens
, vol.33
, pp. 2185-2197
-
-
Imprialos, K.P.1
Sarafidis, P.A.2
Karagiannis, A.I.3
-
71
-
-
77649116361
-
Diuretics in clinical practice. Part I: Mechanisms of action, pharmacological effects and clinical indications of diuretic compounds
-
Sarafidis PA, Georgianos PI, Lasaridis AN. Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds. Expert Opin Drug Saf 2010; 9: 243-57.
-
(2010)
Expert Opin Drug Saf
, vol.9
, pp. 243-257
-
-
Sarafidis, P.A.1
Georgianos, P.I.2
Lasaridis, A.N.3
-
72
-
-
33845497759
-
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome
-
Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diab Care 2006; 29: 2592-7.
-
(2006)
Diab Care
, vol.29
, pp. 2592-2597
-
-
Bakris, G.1
Molitch, M.2
Hewkin, A.3
-
73
-
-
84898854471
-
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
-
Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-75.
-
(2014)
J am Soc Hypertens
, vol.8
, pp. 262-275
-
-
Baker, W.L.1
Smyth, L.R.2
Riche, D.M.3
-
74
-
-
84920544038
-
Prevalence of whitecoat and masked hypertension in national and international registries
-
Gorostidi M, Vinyoles E, Banegas JR, et al. Prevalence of whitecoat and masked hypertension in national and international registries. Hypertens Res 2015; 38: 1-7.
-
(2015)
Hypertens Res
, vol.38
, pp. 1-7
-
-
Gorostidi, M.1
Vinyoles, E.2
Banegas, J.R.3
-
75
-
-
84859895463
-
Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: A perspective
-
Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens 2012; 30: 874-6.
-
(2012)
J Hypertens
, vol.30
, pp. 874-876
-
-
Doumas, M.1
Anyfanti, P.2
Bakris, G.3
-
76
-
-
0038581685
-
Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension
-
Clement DL, De Buyzere ML, De Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-15.
-
(2003)
N Engl J Med
, vol.348
, pp. 2407-2415
-
-
Clement, D.L.1
de Buyzere, M.L.2
de Bacquer, D.A.3
-
77
-
-
54449099978
-
Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: A systematic review and meta-analysis
-
Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2008; 26: 1290-9.
-
(2008)
J Hypertens
, vol.26
, pp. 1290-1299
-
-
Conen, D.1
Bamberg, F.2
-
78
-
-
34848883594
-
Prognostic accuracy of day vs. Night ambulatory blood pressure: A cohort study
-
Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day vs. night ambulatory blood pressure: a cohort study. Lancet 2007; 370: 1219-29.
-
(2007)
Lancet
, vol.370
, pp. 1219-1229
-
-
Boggia, J.1
Li, Y.2
Thijs, L.3
-
79
-
-
84958125420
-
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on reninangiotensin system blockade
-
Weber MA, Mansfield TA, Alessi F, et al. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on reninangiotensin system blockade. Blood Press 2016; 25: 93-103.
-
(2016)
Blood Press
, vol.25
, pp. 93-103
-
-
Weber, M.A.1
Mansfield, T.A.2
Alessi, F.3
-
80
-
-
84915738767
-
Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker
-
Weber MA, Mansfield TA, Alessi F, et al. Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker. Circulation 2013; 128: A13144.
-
(2013)
Circulation
, vol.128
-
-
Weber, M.A.1
Mansfield, T.A.2
Alessi, F.3
-
81
-
-
84959460390
-
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: A randomised, double-blind, placebo-controlled, phase 3 study
-
Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 2016; 4: 211-20.
-
(2016)
Lancet Diabetes Endocrinol
, vol.4
, pp. 211-220
-
-
Weber, M.A.1
Mansfield, T.A.2
Cain, V.A.3
-
82
-
-
84915738766
-
Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen
-
Weber MA, Mansfield TA, T’joen C, et al. Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen. Circulation 2013; 128: A13165.
-
(2013)
Circulation
, vol.128
-
-
Weber, M.A.1
Mansfield, T.A.2
T’Joen, C.3
-
83
-
-
84880850027
-
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
-
Lambers-Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-62.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 853-862
-
-
Lambers-Heerspink, H.J.1
de Zeeuw, D.2
Wie, L.3
-
84
-
-
84953638180
-
Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension
-
Townsend RR, Machin I, Ren J, et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich) 2016; 18: 43-52.
-
(2016)
J Clin Hypertens (Greenwich)
, vol.18
, pp. 43-52
-
-
Townsend, R.R.1
Machin, I.2
Ren, J.3
-
85
-
-
84928196614
-
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
-
Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-8.
-
(2015)
Diabetes Care
, vol.38
, pp. 420-428
-
-
Tikkanen, I.1
Narko, K.2
Zeller, C.3
-
86
-
-
84882251091
-
Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis
-
Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-74.
-
(2013)
Ann Intern Med
, vol.159
, pp. 262-274
-
-
Vasilakou, D.1
Karagiannis, T.2
Athanasiadou, E.3
-
87
-
-
84921811268
-
Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition
-
OP 01 SGLT2 inhibitors
-
Ferrannini G, Hach T, Crowe S, et al et al. Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition. Diabetologia 2014; OP#3 (OP 01 SGLT2 inhibitors).
-
(2014)
Diabetologia
, Issue.3
-
-
Ferrannini, G.1
Hach, T.2
Crowe, S.3
-
89
-
-
84897447957
-
Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
-
Bays HE, Weinstein R, Law G, et al. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014; 22: 1042-9.
-
(2014)
Obesity (Silver Spring)
, vol.22
, pp. 1042-1049
-
-
Bays, H.E.1
Weinstein, R.2
Law, G.3
-
90
-
-
82955194914
-
Thinking beyond traditional cardiovascular risk factors: The role of arterial stiffness in targeting residual risk
-
Katsiki N, Koumaras C, Athyros VG, et al. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012; 63: 9-11.
-
(2012)
Angiology
, vol.63
, pp. 9-11
-
-
Katsiki, N.1
Koumaras, C.2
Athyros, V.G.3
-
91
-
-
84943542801
-
Arterial stiffness and emerging biomarkers: Still a long journey to go
-
Doumas M, Papademetriou V, Athyros V, et al. Arterial stiffness and emerging biomarkers: still a long journey to go. Angiology 2015; 66: 901-3.
-
(2015)
Angiology
, vol.66
, pp. 901-903
-
-
Doumas, M.1
Papademetriou, V.2
Athyros, V.3
-
92
-
-
77949557153
-
Prediction of cardiovascular events and all cause mortality with arterial stiffness: A systematic review and meta-analysis
-
Vlachopoulos C, Aznaouridis K, Stefanidis C. Prediction of cardiovascular events and all cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-27.
-
(2010)
J am Coll Cardiol
, vol.55
, pp. 1318-1327
-
-
Vlachopoulos, C.1
Aznaouridis, K.2
Stefanidis, C.3
-
93
-
-
84892959743
-
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
-
Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 28
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
-
94
-
-
84903528312
-
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
-
Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE 2014; 9: e100777.
-
(2014)
Plos ONE
, pp. 9
-
-
Terami, N.1
Ogawa, D.2
Tachibana, H.3
-
95
-
-
0015122757
-
Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects
-
Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-9.
-
(1971)
Scand J Clin Lab Invest
, vol.28
, pp. 101-109
-
-
Mogensen, C.E.1
-
96
-
-
33644688031
-
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
-
Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-34.
-
(2005)
Diabetes
, vol.54
, pp. 3427-3434
-
-
Rahmoune, H.1
Thompson, P.W.2
Ward, J.M.3
-
97
-
-
84872400230
-
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
-
Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013; 304: F156-67.
-
(2013)
Am J Physiol Renal Physiol
, vol.304
, pp. F156-F167
-
-
Vallon, V.1
Rose, M.2
Gerasimova, M.3
-
98
-
-
84255185190
-
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
-
Thomson S, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75-83.
-
(2012)
Am J Physiol Regul Integr Comp Physiol
, vol.302
, pp. R75-R83
-
-
Thomson, S.1
Rieg, T.2
Miracle, C.3
-
99
-
-
85020530779
-
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
-
Gorriz JL, Nieto J, Navarro-Gonzalez JF, et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med 2015; 4: 1866-89.
-
(2015)
J Clin Med
, vol.4
, pp. 1866-1889
-
-
Gorriz, J.L.1
Nieto, J.2
Navarro-Gonzalez, J.F.3
-
100
-
-
84878060305
-
Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats
-
Kojima N, Williams J, Takahashi T, et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 2013; 345: 464-72.
-
(2013)
J Pharmacol Exp Ther
, vol.345
, pp. 464-472
-
-
Kojima, N.1
Williams, J.2
Takahashi, T.3
-
101
-
-
84892588641
-
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice
-
Vallon V, Gerasimova M, Rose M, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice. Am J Physiol Renal Physiol 2014; 306: F194-204.
-
(2014)
Am J Physiol Renal Physiol
, vol.306
, pp. F194-F204
-
-
Vallon, V.1
Gerasimova, M.2
Rose, M.3
-
102
-
-
84905238756
-
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
-
Gembardt F, Bartaun C, Jarzebska N, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 2014; 307: F317-25.
-
(2014)
Am J Physiol Renal Physiol
, vol.307
, pp. F317-F325
-
-
Gembardt, F.1
Bartaun, C.2
Jarzebska, N.3
-
103
-
-
84897394040
-
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
-
Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney International 2014; 85: 962-71.
-
(2014)
Kidney International
, vol.85
, pp. 962-971
-
-
Kohan, D.E.1
Fioretto, P.2
Tang, W.3
-
104
-
-
84876311251
-
Efficacy and safety of canagliflozin in subject swith type 2 diabetes and chronic kidney disease
-
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subject swith type 2 diabetes and chronic kidney disease. Diabetes Obesity and Metabolism 2013; 15: 463-73.
-
(2013)
Diabetes Obesity and Metabolism
, vol.15
, pp. 463-473
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
105
-
-
84912527805
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
-
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obesity and Metabolism 2014; 16: 1016-27.
-
(2014)
Diabetes Obesity and Metabolism
, vol.16
, pp. 1016-1027
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
106
-
-
84899961819
-
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial
-
Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 369-84.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 369-384
-
-
Barnett, A.H.1
Mithal, A.2
Manassie, J.3
-
107
-
-
79957858617
-
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: A collaborative metaanalysis of high-risk population cohorts
-
van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: A collaborative metaanalysis of high-risk population cohorts. Kidney Int 2011; 79: 1341-52
-
(2011)
Kidney Int
, vol.79
, pp. 1341-1352
-
-
van Der Velde, M.1
Matsushita, K.2
Coresh, J.3
-
108
-
-
79960205374
-
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
-
Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3-46.
-
(2011)
Atherosclerosis
, vol.217
, pp. 3-46
-
-
Catapano, A.L.1
Reiner, Z.2
de Backer, G.3
-
109
-
-
84923524414
-
Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy
-
Hardy E, Ptanszynska A, de Bruin TWA, et al. Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy. Diabetologia 2013; Suppl. #947: 61.
-
(2013)
Diabetologia
, Issue.947
, pp. 61
-
-
Hardy, E.1
Ptanszynska, A.2
de Bruin, T.3
-
110
-
-
84899960517
-
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: A pooled analysis of clinical studies
-
Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 2014; 14: 37.
-
(2014)
BMC Endocr Disord
, vol.14
, pp. 37
-
-
Sinclair, A.1
Bode, B.2
Harris, S.3
-
111
-
-
84899941589
-
Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: Pooled data from four pivotal phase III trials
-
Hach T, Gerich J, Salsali A, et al. Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: pooled data from four pivotal phase III trials. Diabetes 2013; 62 (Suppl 1): LB19.
-
(2013)
Diabetes
, vol.62
-
-
Hach, T.1
Gerich, J.2
Salsali, A.3
-
112
-
-
33750606061
-
Long-term follow-up of patients with NAFLD and elevated liver enzymes
-
Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73
-
(2006)
Hepatology
, vol.44
, pp. 865-873
-
-
Ekstedt, M.1
Franzen, L.E.2
Mathiesen, U.L.3
-
113
-
-
34547673500
-
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients
-
Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.
-
(2007)
Diabetes Care
, vol.30
, pp. 2119-2121
-
-
Targher, G.1
Bertolini, L.2
Rodella, S.3
-
114
-
-
84947786115
-
Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
-
Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015; 7: 104.
-
(2015)
Diabetol Metab Syndr
, vol.7
, pp. 104
-
-
Qiang, S.1
Nakatsu, Y.2
Seno, Y.3
-
115
-
-
84962210716
-
Ipragliflozin, a sodiumglucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats
-
[Epub ahead of print]
-
Nishimura N, Kitade M, Noguchi R, et al. Ipragliflozin, a sodiumglucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. J Gastroenterol 2016; [Epub ahead of print]
-
(2016)
J Gastroenterol
-
-
Nishimura, N.1
Kitade, M.2
Noguchi, R.3
-
116
-
-
84953791948
-
The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice
-
Honda Y, Imajo K, Kato T, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One 2016; 11: e0146337.
-
(2016)
Plos One
, pp. 11
-
-
Honda, Y.1
Imajo, K.2
Kato, T.3
-
117
-
-
84975698839
-
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOMER trial
-
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOMER trial. Eur Heart J 2016; 37: 1526-34.
-
(2016)
Eur Heart J
, vol.37
, pp. 1526-1534
-
-
Fitchett, D.1
Zinman, B.2
Wanner, C.3
-
118
-
-
85020860519
-
-
FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10 mg, Food and Drug Administration. Available from: (http://www.fda.gov/DOWNLOADS/ADVISORYCOMMITTEES/COMMITTEESMEETINGMATERIALS/DRUGS/ENDOCRINOLOGICANDMETABOLICDRUGSADVISORYCOMMITTEE/UCM262994.bPDF).
-
Dapagliflozin Tablets 5 and 10 Mg, Food and Drug Administration
-
-
-
119
-
-
72649106871
-
-
FDA briefing material NDA 204042. Food and Drug Administation. Available from: (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf)
-
Food and Drug Administation
-
-
-
120
-
-
84962613532
-
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis
-
Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4: 411-9.
-
(2016)
Lancet Diabetes Endocrinol
, vol.4
, pp. 411-419
-
-
Wu, J.H.1
Foote, C.2
Blomster, J.3
-
121
-
-
85005950931
-
Stroke paradox with SGLT-2 inhibitors: A play of chance or a viscosity-mediated reality?
-
Imprialos KP, Boutari C, Stavropoulos K, et al. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry. 2016. Article in press. DOI: 10.1136/jnnp-2016-314704.
-
(2016)
J Neurol Neurosurg Psychiatry
-
-
Imprialos, K.P.1
Boutari, C.2
Stavropoulos, K.3
|